# US 2026/0090953 A1 · Gastrointestinal Capsule and Treatment Method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0090953 A1
- Document ID: US20260090953A1
- Status: Published application
- Kind: A1
- Application number: 19/352,488
- Filed: 2025-10-08
- Published: 2026-04-02
- Earliest claimed: 2017-06-11
- Assignees: Vibrant Corporation
- Applicants: Vibrant Ltd.
- Inventors: Lior Ben-Tsur; Camille Morliere; Ronny Shabbat
- Web page: https://patentgrep.com/patent/US20260090953A1

## CPC

- A61B 5/4836: {Diagnosis combined with treatment in closed-loop systems or methods (A61B5/0036 takes precedence)}
- A61H 23/0263: {using rotating unbalanced masses}
- A61B 5/6861: {Capsules, e.g. for swallowing or implanting}
- A61B 5/01: Measuring temperature of body parts {; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue} (clinical contact thermometers G01K13/20)
- A61B 5/14539: {for measuring pH}
- A61B 2562/029: Humidity sensors
- A61H 2201/1215: Rotary drive
- A61H 2201/16: Physical interface with patient
- A61H 2201/5007: computer controlled
- A61H 2205/083: Abdomen
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61H: PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY (electrotherapy, magnetotherapy, radiation therapy or ultrasound therapy A61N)

## Abstract

A gastrointestinal capsule and treatment methods utilizing such a capsule, the capsule including: (a) a capsule housing having a longitudinal axis; (b) at least one thrusting mechanism, disposed within the housing, the thrusting mechanism adapted to exert forces on the housing such that, when the capsule is disposed within a gastrointestinal tract of a user, and the mechanism is in an active mode, the gastrointestinal capsule exerts forces against, or in a direction of, the walls of the tract; and (c) a power supply adapted to power the mechanism. The gastrointestinal capsule is used in a method for treating a sensation of straining during defecating and/or for increasing a Bristol stool score of fecal matter of a subject by the gastrointestinal capsule being ingested by the subject and activated in a targeted zone of the gastrointestinal tract of the subject.

## Claims

### Claim 1

A method of treating a sensation of straining while defecating in a human subject using a gastrointestinal capsule adapted to transit an alimentary canal of the subject, said capsule having:
a housing;
a battery, disposed within said housing; and
a vibrating agitation mechanism, powered by said battery, said vibrating agitation mechanism adapted such that, in a first vibrating mode of operation, said housing exerts vibrations on an environment surrounding said capsule, the method comprising:
(a) ingesting said gastrointestinal capsule; and
(b) controlling said vibrating agitation mechanism such that said first vibrating mode of operation occurs when said capsule is disposed within a targeted zone within a gastrointestinal tract of the subject, so as to alleviate or dissipate the sensation of straining while defecating.

### Claim 2 (depends on 1)

The method of claim 1, said controlling including pre-setting an activation time delay of said capsule, prior to said ingesting.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject is a particular subject and wherein said pre-setting of said activation time delay is according to a measured or estimated transit time of chyme along said gastrointestinal tract of said particular subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a subject who has experienced at most one of the following symptoms over the preceding 3 months:
fewer than three bowel movements per week;
straining;
lumpy or hard stools;
sensation of anorectal obstruction;
sensation of incomplete defecation; and
manual maneuvering required to defecate.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a subject who has experienced at most one of the following symptoms over the preceding 3 months:
fewer than three bowel movements per week;
straining during more than 25% of defecations;
lumpy or hard stools in more than 25% of defecations;
sensation of incomplete defecation in more than 25% of defecations;
sensation of anorectal obstruction in more than 25% of defecations; and
manual maneuvering required to facilitate more 25% of defecations.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a constipation free subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein said subject suffers from at least one of emotional stress and psychosomatically induced symptoms.

### Claim 8 (depends on 1)

The method of claim 1, wherein said ingesting and controlling together form a treatment session, and wherein said method includes administering to the subject at least one said treatment session.

### Claim 9 (depends on 8)

The method of claim 8, wherein said administering to the subject at least one treatment session includes administering to the subject a plurality of treatment sessions.

### Claim 10 (depends on 9)

The method of claim 9, wherein said administering a plurality of treatment sessions includes administering 1 to 7 said treatment sessions per week, over a treatment period of at least two weeks.

### Claim 11

A method of increasing a Bristol stool score of fecal matter defecated by a human subject using a gastrointestinal capsule adapted to transit an alimentary canal of the subject, said capsule having:
a housing;
a battery, disposed within said housing; and
a vibrating agitation mechanism, powered by said battery, said vibrating agitation mechanism adapted such that, in a first vibrating mode of operation, said housing exerts vibrations on an environment surrounding said capsule, the method comprising:
(a) ingesting said gastrointestinal capsule; and
(b) controlling said vibrating agitation mechanism such that said first vibrating mode of operation occurs when said capsule is disposed within a targeted zone within a gastrointestinal tract of the subject, so as to increase the Bristol stool score of the fecal matter defecated by the subject.

### Claim 12 (depends on 11)

The method of claim 11, said controlling including pre-setting an activation time delay of said capsule, prior to said ingesting.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject is a particular subject and wherein said pre-setting of said activation time delay is according to a measured or estimated transit time of chyme along said gastrointestinal tract of said particular subject.

### Claim 14 (depends on 11)

The method of claim 11, wherein the subject is a subject who has experienced at most one of the following symptoms over the preceding 3 months:
fewer than three bowel movements per week;
straining;
lumpy or hard stools;
sensation of anorectal obstruction;
sensation of incomplete defecation; and
manual maneuvering required to defecate.

### Claim 15 (depends on 11)

The method of claim 11, wherein the subject is a subject who has experienced at most one of the following symptoms over the preceding 3 months:
fewer than three bowel movements per week;
straining during more than 25% of defecations;
lumpy or hard stools in more than 25% of defecations;
sensation of incomplete defecation in more than 25% of defecations;
sensation of anorectal obstruction in more than 25% of defecations; and
manual maneuvering required to facilitate more 25% of defecations.

### Claim 16 (depends on 11)

The method of claim 11, wherein the subject is a constipation free subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein said subject suffers from at least one of emotional stress and psychosomatically induced symptoms.

### Claim 18 (depends on 11)

The method of claim 11, wherein said ingesting and controlling together form a treatment session, and wherein said method includes administering to the subject at least one said treatment session.

### Claim 19 (depends on 18)

The method of claim 18, wherein said administering to the subject at least one treatment session includes administering to the subject a plurality of treatment sessions.

### Claim 20 (depends on 19)

The method of claim 19, wherein said administering a plurality of treatment sessions includes administering 1 to 7 said treatment sessions per week, over a treatment period of at least two weeks.
